Why It Matters
Congress and federal agencies are aggressively phasing out animal testing in drug development, creating crisis and opportunity for Charles River Laboratories. The company faces genuine business threats from bipartisan legislation like the FDA Modernization Act 3.0, HEARTS Act, and SPARE Act that would curtail animal research funding. A critical shortage of non-human primates—driven by import restrictions—threatens research models the company supplies.
By the Numbers
Charles River Laboratories filed a $90,000 third quarter lobbying disclosure with BGR Government Affairs, marking a strategic escalation after nearly two decades in the lobbying arena.
The contract research organization has accumulated 69 prior disclosures totaling over $2 million since 2007, previously working with four other firms. BGR represents a significant upgrade, handling major pharmaceutical clients including GSK, Pfizer, and Amgen.
BGR assigned three strategically positioned lobbyists: Remy Leigh Brim Mason, a former Senate HELP Committee senior adviser with a PhD in pharmacology; John W. Stone, former House Energy and Commerce Committee senior counsel; and Maya Seiden, specializing in international trade and supply chain issues.
The Agenda
Charles River is implementing a two pronged approach: lobbying on non-human primate supply chain protection and in vitro research alternatives development. This dual focus reflects Congress’s push to reduce animal testing through multiple advancing bills.
The company is playing both offense and defense. Defensively, it’s advocating to maintain access to research primates still essential when alternatives don’t exist. Offensively, it’s positioning itself as a leader in developing validated alternative testing technologies.
Congressional momentum is strong. House Energy and Commerce Committee leadership has praised AI modeling and organ-on-chip testing, while Senators Rand Paul (R-KY) and Cory Booker (D-NJ) lead bipartisan modernization efforts. However, a 2023 National Academies report documented critical gaps in primate research infrastructure.
Between The Lines
The FDA announced plans to phase out animal testing requirements for certain drugs while NIH declared it would prioritize human-focused research. Multiple bills are advancing with bipartisan support, creating genuine legislative momentum.
However, lawmakers acknowledge that alternative technologies remain incomplete. Supply chain constraints for non-human primates add pressure as major suppliers ceased imports from Cambodia due to regulatory restrictions, creating research needs alternatives cannot yet fill.
Charles River faces a critical inflection point: regulatory pressure to develop alternatives while managing constraints that make continued animal access necessary near-term.
The Bottom Line
Charles River’s $90,000 investment positions it to navigate pivotal biomedical research changes. The dual lobbying strategy—securing primate supply chains while promoting alternatives—hedges bets in a rapidly shifting regulatory environment. With lobbyists holding key committee experience on both House Energy and Commerce and Senate HELP—the committees driving this transformation—Charles River is essentially betting it can influence the pace and scope of change that could reshape its entire business model.
For more detailed insights access Legis1. Request a demo today!